Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUIBRON-T/SR vs AMINOPHYLLINE DYE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors.
Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.
Treatment of symptoms and prevention of asthma,Treatment of reversible bronchospasm associated with chronic bronchitis and emphysema
Treatment of bronchospasm associated with asthma, chronic bronchitis, emphysema, and COPD,Apnea of prematurity (off-label)
200-400 mg orally every 12 hours; extended-release tablets. Initial dose 200 mg every 12 hours; may increase by 200 mg daily every 3-7 days based on serum theophylline levels (target 5-15 mcg/m L). Maximum 800 mg/day.
Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).
Terminal t1/2: 3-12 hours (adults); 1-9 hours (children); prolonged in cirrhosis (up to 30 hours), heart failure, elderly. Clinical context: Narrow therapeutic index (5-15 mcg/m L); dosing interval adjusted based on t1/2.
Terminal elimination half-life is approximately 7-9 hours in healthy adults. In smokers, half-life decreases to 4-5 hours. In patients with hepatic cirrhosis, heart failure, or COPD, half-life may prolong to 20-30 hours.
Hepatic via CYP1A2, CYP2E1, and CYP3A4; undergoes N-demethylation and oxidation. Saturable kinetics.
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4, CYP2E1, and CYP2D6. Metabolism may be saturated, leading to nonlinear kinetics at therapeutic doses.
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4): 90% to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid). Biliary/fecal: minimal (<5%).
Primarily hepatic metabolism (approximately 90%) to 1,3-dimethyluric acid and other metabolites; renal excretion of unchanged drug accounts for about 10-13% of the dose. Less than 1% is excreted via bile or feces.
~40% bound to albumin. Binding is reversible and non-saturable.
Approximately 40% bound, primarily to albumin. In neonates, protein binding is lower (about 30%).
Vd: 0.3-0.7 L/kg (adults); approximates total body water. Increased Vd in premature infants and obesity; decreased in dehydration.
Approximately 0.5 L/kg (range 0.3-0.7 L/kg). Higher in premature infants and neonates (0.6-0.9 L/kg). Vd corresponds to total body water; aminophylline distributes into extracellular and intracellular fluid.
Oral: 100% (immediate-release); 90-100% for SR formulations (dose-dependent slightly lower).
Oral immediate-release: nearly 100%. Oral sustained-release: 80-100% depending on formulation. Rectal: variable (80-100%). Intravenous: 100%.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: use 75% of normal dose, monitor levels. GFR <10 m L/min: use 50% of normal dose, monitor levels. Dose frequency unchanged.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min: reduce dose by 50% and monitor serum theophylline levels closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%, monitor levels. Child-Pugh C: reduce dose by 70%, monitor levels. Use immediate-release forms preferred.
Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: use alternative therapy or reduce dose by 80-90% with close monitoring.
6-12 years: 10-16 mg/kg/day in divided doses every 12 hours (extended-release). 12-16 years: 12-18 mg/kg/day; target serum theophylline 5-15 mcg/m L. Maximum 800 mg/day.
Loading dose: 5-6 mg/kg IV over 30 minutes. Maintenance IV infusion: age 1-6 months: 0.5 mg/kg/hour; 6-12 months: 0.6-0.7 mg/kg/hour; 1-9 years: 0.8-1.0 mg/kg/hour; >9 years: 0.5-0.7 mg/kg/hour. Oral: 5-6 mg/kg every 6 hours (immediate-release) or every 12 hours (extended-release).
Initiate at lower end of dosing (200-400 mg/day). Monitor serum concentrations due to decreased clearance. Avoid doses >400 mg/day without level monitoring. Titrate cautiously.
Lower initial doses recommended (e.g., 300-400 mg/day oral) with slower titration, as clearance is decreased. Monitor serum theophylline levels and adjust to achieve 5-15 mcg/m L.
No FDA black box warning.
Theophylline has a narrow therapeutic index; serum levels must be monitored. Severe toxicity can occur at levels above 20 mcg/m L, including seizures, cardiac arrhythmias, and death. Use with caution as serious adverse effects may occur without warning.
Seizures may occur at therapeutic levels,Use caution in patients with peptic ulcer, seizure disorders, cardiac arrhythmias,Monitor serum theophylline levels to avoid toxicity,Drug interactions with fluoroquinolones, cimetidine, macrolides, and allopurinol
Monitor serum theophylline levels; adjust dose accordingly,Risk of toxicity is increased in patients with hepatic impairment, congestive heart failure, cor pulmonale, and elderly patients,May exacerbate or induce peptic ulcer disease, seizures, and other cardiac arrhythmias,Concurrent use with other xanthines can increase toxicity,Smoking cessation decreases clearance and may require dose reduction
Hypersensitivity to theophylline or any component,History of seizure disorder (relative),Active peptic ulcer disease (relative)
Hypersensitivity to theophylline or any component,Active seizure disorder unless adequately controlled with medications,Severe cardiac arrhythmias (e.g., ventricular tachycardia),Pregnancy (controversial; use only if clearly needed)
Avoid charcoal-grilled meats and high-protein, low-carbohydrate diets which can decrease theophylline clearance. Caffeine-containing foods/beverages may potentiate adverse effects. Consistent dietary habits are recommended to maintain stable drug levels.
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. High-fat meals may slow absorption of extended-release formulations. No other significant food interactions.
Theophylline (active ingredient) is not teratogenic in humans. First trimester: No increased risk of major malformations from epidemiological studies. Second/third trimester: No specific fetal risks; however, high maternal serum levels may cause neonatal toxicity (jitteriness, tachycardia) if near term.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of fetal tachycardia, jitteriness, and hypoglycemia due to maternal theophylline levels; no clear teratogenic signal. Close monitoring recommended.
Theophylline is excreted into breast milk with M/P ratio approximately 0.6-0.7. Relative infant dose is less than 10% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for irritability or insomnia. Use lowest effective maternal dose.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant serum levels are typically subtherapeutic, but irritability, jitteriness, and feeding intolerance have been reported. Caution advised; monitor infant for adverse effects. Benefit-risk assessment required.
During pregnancy, theophylline clearance may decrease by 20-30% in third trimester due to reduced hepatic metabolism and increased volume of distribution. Monitor serum levels frequently and reduce dose by 10-20% if levels exceed therapeutic range; individualize dosing based on clinical response and drug monitoring.
Pregnancy increases theophylline clearance by 20-40% due to increased hepatic metabolism and renal blood flow. Monitor serum levels and adjust dose to maintain therapeutic range. Consider extended-release formulations for stable levels. Postpartum: clearance may decrease rapidly, requiring dose reduction.
Quibron-T/SR is a sustained-release theophylline formulation used for asthma and COPD. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L); levels >20 mcg/m L increase toxicity risk. Cimetidine, ciprofloxacin, and erythromycin decrease clearance, requiring dose reduction. Smoking induces metabolism, requiring higher doses. Use with caution in patients with heart failure, hepatic impairment, or fever.
Aminophylline is a bronchodilator that contains theophylline and ethylenediamine. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Avoid use in patients with active peptic ulcer disease. Ethylenediamine component may cause allergic reactions in sensitive patients. Dose adjustment required in hepatic impairment, heart failure, or elderly. Tachyphylaxis may occur with prolonged use. Cigarette smoking increases clearance; monitor levels closely. Consider drug interactions with cimetidine, fluoroquinolones, and macrolides which decrease clearance.
Take exactly as prescribed; do not crush or chew sustained-release tablets.,Avoid excessive caffeine intake (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not stop abruptly; tapering may be needed.,Keep regular appointments for blood level monitoring.,Inform all healthcare providers of this medication.
Do not chew or crush extended-release tablets; swallow whole.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity such as nausea, vomiting, insomnia, rapid heartbeat, or seizures immediately.,Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Inform your doctor if you have a history of seizures, ulcers, or liver disease.,Do not smoke or stop smoking without medical advice as it affects how this medication works.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUIBRON-T/SR vs AMINOPHYLLINE DYE FREE, answered by our medical review team.
QUIBRON-T/SR is a Xanthine Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors.. AMINOPHYLLINE DYE FREE is a Xanthine Bronchodilator that works by Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUIBRON-T/SR and AMINOPHYLLINE DYE FREE depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUIBRON-T/SR is: 200-400 mg orally every 12 hours; extended-release tablets. Initial dose 200 mg every 12 hours; may increase by 200 mg daily every 3-7 days based on serum theophylline levels (target 5-15 mcg/m L). Maximum 800 mg/day.. The standard adult dose of AMINOPHYLLINE DYE FREE is: Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUIBRON-T/SR and AMINOPHYLLINE DYE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUIBRON-T/SR is classified as Category C. Theophylline (active ingredient) is not teratogenic in humans. First trimester: No increased risk of major malformations from epidemiological studies. Second/third trimester: No sp. AMINOPHYLLINE DYE FREE is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.